Daily Bio News Summary — 2026-10-13: Two licensing deals, two late-stage disappointments and a CEO exit

Tuesday’s harvest produced ten items across six of the eleven sources the daily sweep covers — BioSpace, Fierce Biotech, Fierce Pharma, BioPharma Dive and the PR-wire feeds contributed, with the wire-style and paywalled trade sources contributing little that was not already on file. The batch splits into three shapes: cross-border licensing, clinical readouts that went both ways, and corporate leadership moves. There were no FDA approvals in the set and no financings.

Two cross-border licensing deals

The most consequential item of the day was Roche’s obesity move. The company has licensed an asset from China-based RNAi developer Rona Therapeutics in a deal valued at roughly $1.16 billion, per the BioSpace report (2026-10-13). The headline frames this as Roche continuing to expand its metabolic pipeline via licensing rather than in-house discovery — the same framing appeared in a second version of the story carried by Pharmaphorum, which put the value at $1.16bn for the same transaction.

Pfizer’s agreement with Enodia Therapeutics is the smaller but strategically interesting deal. Worth up to $500 million, it covers small molecules designed to eliminate pathogenic proteins at the point of synthesis (BioSpace, 2026-10-13). Pfizer’s venture arm co-led the biotech’s seed round earlier this year, according to the same report — a reminder that corporate venture money frequently precedes the licensing conversation.

Late-stage setbacks

BioNTech’s mRNA-based cancer vaccine failed a Phase 3 test in head and neck cancer (Fierce Biotech, 2026-10-13). The readout matters beyond one program: this is the company’s lead therapeutic cancer vaccine candidate, and a Phase 3 miss in the indication it had prioritised will shape how the market values the rest of the mRNA oncology franchise. A separate Endpoints News headline on the same story described the trial as missing the first of two goals; that version sat behind the paywall and was not written to the site.

Syndax Pharmaceuticals is ending development of Niktimvo in lung fibrosis after a mid-stage study failed (BioSpace, 2026-10-13). Niktimvo is an approved product for a different indication, so this is a label-expansion program being closed rather than a commercial retreat — but it removes a growth vector the company had been promoting.

A third dataset belongs in this section even though it landed under a roundup headline: Merck released data for its experimental eye drug in diabetic macular edema, characterised in the BioPharma Dive roundup as awaited and in an Endpoints News headline as mixed against a Lucentis competitor (2026-10-13). Eye-drug readouts have been a recurring theme on the site this month.

Where the readouts went the other way

Bristol Myers Squibb reported pivotal-trial wins in both lung disease and a solid tumor (Fierce Biotech, 2026-10-12). Coming a day after two other late-stage BMS readouts, the pair reinforces the picture of a company converting mid-stage assets into registration-track data.

Mirum Pharmaceuticals notched a Phase 3 win that opens a third rare liver indication for Livmarli (Fierce Pharma, 2026-10-12). Rare-disease label expansions are one of the few reliable value-creation events left in a market that has been stingy with them this month.

Pipeline triage

Nurix Therapeutics is dropping one of its BTK-targeted programs while momentum builds behind a partnered asset that is moving into Phase 3 (Fierce Biotech, 2026-10-13). The company’s pitch rests on targeted protein degradation, and the decision to discontinue one asset while advancing another is the kind of portfolio triage that becomes common when a platform company has more shots than capital.

People and company creation

Bausch + Lomb is replacing chief executive Brent Saunders, who is exiting the eye-care company for a second time, and has named an interim successor (Fierce Pharma, 2026-10-12). The BioPharma Dive roundup of the same day carried the CEO change as its lead item. Saunders is a serial operator whose departures have historically preceded strategic resets.

The most structurally interesting personnel move came from the company-creation side. Biotech builder Paragon Labs installed several members of Apogee Therapeutics’ former leadership team after AbbVie’s $10.9 billion acquisition of Apogee — the same morning its ninth spinout, Velaris Therapeutics, was acquired by Alaunos Therapeutics (Fierce Biotech, 2026-10-13). The episode is a compact illustration of how the platform-company-creation model recycles talent and assets within a single morning.

What this batch is NOT telling us

Several things that have driven recent batches are absent today. There are no FDA approvals or complete response letters — the day’s regulatory content is entirely clinical data. There is no AI-in-bio news, no IPO pricing, no China-only regulatory action, and no manufacturing or supply-chain story. Notably, no new financings were written: the two IPO-pricing items that surfaced in the candidate set (TRex Bio and Retension) were follow-ups to an IPO filing already covered on the site, and were held back as duplicates. And because Endpoints News and several trade sources gate most of their coverage, a meaningful share of Tuesday’s trade reporting — including the Paragon spinout write-up and the Dutch court ruling on subcutaneous Keytruda — was visible in the candidate set but could not be verified as freely readable, and so was not published.

Reading order

If you have five minutes: the Roche–Rona licensing deal, the BioNTech Phase 3 miss, the BMS pivotal wins, the Pfizer–Enodia pact in protein degradation, and the Paragon/Apogee leadership move. Those five cover the batch’s deal, setback, momentum, platform and talent threads.

How to read the underlying articles

Every item summarised above corresponds to a markdown file in src/content/news/. Each file carries sourceUrl (the original article), sourceName and pubDate, so the primary reporting is one click away. Nothing in this summary asserts a fact that is not present in those frontmatter fields.

The full batch

1. Roche expands obesity R&D footprint with Rona deal worth $1B+ — BioSpace, 2026-10-13
2. Pfizer pens $500M+ deal with Enodia to destroy disease-causing proteins — BioSpace, 2026-10-13
3. Syndax ends fibrosis program for Niktimvo after mid-stage disappointment — BioSpace, 2026-10-13
4. BioNTech’s mRNA cancer vaccine fails phase 3 test — Fierce Biotech, 2026-10-13
5. BMS doubles up with pivotal wins in lung disease, solid tumor — Fierce Biotech, 2026-10-12
6. Nurix drops BTK degrader, as Roche-partnered asset enters ph. 3 — Fierce Biotech, 2026-10-13
7. Paragon Labs imports Apogee leadership after AbbVie buyout — Fierce Biotech, 2026-10-13
8. Mirum keeps momentum with ph. 3 win for Livmarli — Fierce Pharma, 2026-10-12
9. Bausch + Lomb CEO Brent Saunders hits the exit again — Fierce Pharma, 2026-10-12
10. Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data — BioPharma Dive, 2026-10-13